Answer
The safety and efficacy of Perjeta (pertuzumab) in children and adolescents under 18 have not been established, and there is no relevant paediatric use for breast cancer.
Sources for this answer
- Perjeta 420 mg Concentrate for Solution for InfusionRoche Products Limited · emc · SmPC §4.2 Posology and method of administration · Version 22Document updated
Sources checked